Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | C5 | P01031 | 2/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20402962 | 0.78 | ALDH1A1 (0.55) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12932742 | 0.71 | KMT2A (0.64) | KMT2AMEN1GAACYP3A4CYP2C9 | |
| SCHEMBL12233628 | 0.71 | PDE4A (0.41) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15171954 | 0.69 | MAPT (0.45) | KMT2AMEN1GAACYP3A4CYP2C9 | |
| SCHEMBL12703969 | 0.68 | PDE4A (0.44) | CYP3A4 | |
| SCHEMBL26973723 | 0.68 | SCN5A (0.45) | TAS1R3TAS1R1CYP2C19 | |
| SCHEMBL5180344 | 0.68 | MMP2 (0.42) | FPR2CYP2C9CYP2C19CA12CA1 | |
| SCHEMBL13304417 | 0.68 | TAS1R3 (0.49) | KMT2AMEN1TAS1R3TAS1R1 | |
| SCHEMBL13304426 | 0.68 | TP53 (0.51) | KMT2AMEN1GAA | |
| SCHEMBL10364679 | 0.68 | HSD17B10 (0.42) | KMT2AMEN1GAACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028938-B2 | Antiviral agents and uses thereof | GRIFFITH UNIVERSITY (AU) | 2018-07-24 | — | — | US | disclosed |
| US-20170290809-A1 | ANTIVIRAL AGENTS AND USES THEREOF | GRIFFITH UNIVERSITY (AU) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290809-A1 | ANTIVIRAL AGENTS AND USES THEREOF | RNASE1, ENTPD5, ACE | FPR2 4179/4885KMT2A 3066/4885MEN1 3514/4885 |
| US-10028938-B2 | Antiviral agents and uses thereof | RNASE1, ENTPD5, ACE | FPR2 4179/4885KMT2A 3066/4885MEN1 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.